Get to know our clinical trials
Phase I/IIa clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AZD8421 alone or in combination in patients with selected advanced or metastatic solid tumors (CYCAD-1)
EL OBJETIVO ES INVESTIGAR LA SEGURIDAD Y TOLERABILIDAD, CARACTERIZAR LOS DLT Y DETERMINAR LA DMT Y/O DMF Y/O DOSIS RECOMENDADA DOSIS RECOMENDADA DE FASE II (RP2D) DE AZD8421 COMO MONOTERAPIA Y TAMBIÉN EN COMBINACIÓN CON OTROS MEDICAMENTOS CONTRA EL CÁNCER.
Technical Summary
- PHASE I/IIA, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF AZD8421 ALONE OR IN COMBINATION IN PATIENTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMORS (CYCAD-1)
- Code EudraCT: 2023-507305-33
- Protocol number: D8470C00001
- Promoter: Astra Zeneca AB
- Molecule/Drug: AZD8421
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.